

Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-11-02 | 144 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

Report description:

The global multiple sclerosis therapies market size reached US\$ 25.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 33.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2022-2028.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal antibodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.

Breakup by Drug:

Immunomodulators
Copaxone
Avonex/Plegridy
Gilneya
Tysabri
Betaseron/Extavia
Tecifidera
Rebif
Ampyra
Immunosuppressants
Aubagio
Lemtrada
Ocrelizumab
Zinbryta

Breakup by Drug Type:

Biologic Drugs
Small Molecule Drugs

Breakup by Route of Administration:

Oral
Injectable
Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global multiple sclerosis therapies market?

What are the key regional markets?

What is the breakup of the market based on the drug?

What is the breakup of the market based on the drug type?

What is the breakup of the market based on the route of administration?

What is the breakup of the market based on the distribution channel?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global multiple sclerosis therapies market and who are the key players?

What is the degree of competition in the industry?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
 - 2.1 Objectives of the Study
 - 2.2 Stakeholders
 - 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
 - 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.5Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1Overview
- 4.2Key Industry Trends
- 5 Global Multiple Sclerosis Therapies Market
- 5.1Market Overview
- 5.2Market Performance
- 5.3Impact of COVID-19
- 5.4Market Forecast
- 6 Market Breakup by Drug
- 6.1Immunomodulators
- 6.1.1 Market Trends
- 6.1.2 Major Types
- 6.1.2.1 Copaxone
- 6.1.2.2 Avonex/Plegridy
- 6.1.2.3 Gilneya
- 6.1.2.4 Tysabri
- 6.1.2.5 Betaseron/Extavia
- 6.1.2.6 Tecifidera
- 6.1.2.7 Rebif
- 6.1.2.8 Ampyra
- 6.1.3 Market Forecast
- 6.2Immunosuppressants
- 6.2.1 Market Trends
- 6.2.2 Major Types
- 6.2.2.1 Aubagio
- 6.2.2.2 Lemtrada
- 6.2.2.3 Ocrelizumab
- 6.2.2.4 Zinbryta
- 6.2.3 Market Forecast
- 7 Market Breakup by Drug Type
- 7.1Biologic Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2Small Molecule Drugs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 8 Market Breakup by Route of Administration
- 8.1Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3Intravenous
- 8.3.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.2 Market Forecast
- 9 Market Breakup by Distribution Channel
 - 9.1Hospital Pharmacies
 - 9.1.1 Market Trends
 - 9.1.2 Market Forecast
 - 9.2Retail Pharmacies
 - 9.2.1 Market Trends
 - 9.2.2 Market Forecast
 - 9.3Online Pharmacies
 - 9.3.1 Market Trends
 - 9.3.2 Market Forecast
- 10 Market Breakup by Region
 - 10.1North America
 - 10.1.1 United States
 - 10.1.1.1 Market Trends
 - 10.1.1.2 Market Forecast
 - 10.1.2 Canada
 - 10.1.2.1 Market Trends
 - 10.1.2.2 Market Forecast
 - 10.2Asia Pacific
 - 10.2.1 China
 - 10.2.1.1 Market Trends
 - 10.2.1.2 Market Forecast
 - 10.2.2 Japan
 - 10.2.2.1 Market Trends
 - 10.2.2.2 Market Forecast
 - 10.2.3 India
 - 10.2.3.1 Market Trends
 - 10.2.3.2 Market Forecast
 - 10.2.4 South Korea
 - 10.2.4.1 Market Trends
 - 10.2.4.2 Market Forecast
 - 10.2.5 Australia
 - 10.2.5.1 Market Trends
 - 10.2.5.2 Market Forecast
 - 10.2.6 Indonesia
 - 10.2.6.1 Market Trends
 - 10.2.6.2 Market Forecast
 - 10.2.7 Others
 - 10.2.7.1 Market Trends
 - 10.2.7.2 Market Forecast
 - 10.3Europe
 - 10.3.1 Germany
 - 10.3.1.1 Market Trends
 - 10.3.1.2 Market Forecast
 - 10.3.2 France
 - 10.3.2.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
 - 10.3.3.1 Market Trends
 - 10.3.3.2 Market Forecast
- 10.3.4 Italy
 - 10.3.4.1 Market Trends
 - 10.3.4.2 Market Forecast
- 10.3.5 Spain
 - 10.3.5.1 Market Trends
 - 10.3.5.2 Market Forecast
- 10.3.6 Russia
 - 10.3.6.1 Market Trends
 - 10.3.6.2 Market Forecast
- 10.3.7 Others
 - 10.3.7.1 Market Trends
 - 10.3.7.2 Market Forecast
- 10.4 Latin America
 - 10.4.1 Brazil
 - 10.4.1.1 Market Trends
 - 10.4.1.2 Market Forecast
 - 10.4.2 Mexico
 - 10.4.2.1 Market Trends
 - 10.4.2.2 Market Forecast
 - 10.4.3 Others
 - 10.4.3.1 Market Trends
 - 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
 - 10.5.1 Market Trends
 - 10.5.2 Market Breakup by Country
 - 10.5.3 Market Forecast
- 11 SWOT Analysis
 - 11.1 Overview
 - 11.2 Strengths
 - 11.3 Weaknesses
 - 11.4 Opportunities
 - 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
 - 13.1 Overview
 - 13.2 Bargaining Power of Buyers
 - 13.3 Bargaining Power of Suppliers
 - 13.4 Degree of Competition
 - 13.5 Threat of New Entrants
 - 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
 - 15.1 Market Structure

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.2Key Players
- 15.3Profiles of Key Players
 - 15.3.1Abbvie Inc.
 - 15.3.1.1 Company Overview
 - 15.3.1.2 Product Portfolio
 - 15.3.1.3 Financials
 - 15.3.1.4 SWOT Analysis
 - 15.3.2Bayer Aktiengesellschaft
 - 15.3.2.1 Company Overview
 - 15.3.2.2 Product Portfolio
 - 15.3.2.3 Financials
 - 15.3.2.4 SWOT Analysis
 - 15.3.3Biogen Inc.
 - 15.3.3.1 Company Overview
 - 15.3.3.2 Product Portfolio
 - 15.3.3.3 Financials
 - 15.3.3.4 SWOT Analysis
 - 15.3.4Bristol-Myers Squibb Company
 - 15.3.4.1 Company Overview
 - 15.3.4.2 Product Portfolio
 - 15.3.4.3 Financials
 - 15.3.4.4 SWOT Analysis
 - 15.3.5F. Hoffmann-La Roche AG (Roche Holding AG)
 - 15.3.5.1 Company Overview
 - 15.3.5.2 Product Portfolio
 - 15.3.5.3 SWOT Analysis
 - 15.3.6GlaxoSmithKline Plc
 - 15.3.6.1 Company Overview
 - 15.3.6.2 Product Portfolio
 - 15.3.6.3 Financials
 - 15.3.6.4 SWOT Analysis
 - 15.3.7Merck & Co. Inc.
 - 15.3.7.1 Company Overview
 - 15.3.7.2 Product Portfolio
 - 15.3.7.3 Financials
 - 15.3.7.4 SWOT Analysis
 - 15.3.8Novartis AG
 - 15.3.8.1 Company Overview
 - 15.3.8.2 Product Portfolio
 - 15.3.8.3 Financials
 - 15.3.8.4 SWOT Analysis
 - 15.3.9Sanofi S.A.
 - 15.3.9.1 Company Overview
 - 15.3.9.2 Product Portfolio
 - 15.3.9.3 Financials
 - 15.3.9.4 SWOT Analysis
 - 15.3.10Teva Pharmaceutical Industries Ltd.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis

Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-11-02 | 144 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com